Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
The Lancet. Rheumatology (2021) - Comments
pubmed: 33754144  doi: 10.1016/s2665-9913(21)00070-9  issn: 2665-9913 

Paul C Cremer, Antonio Abbate, Kristin Hudock, Carla McWilliams, Jinesh Mehta, Steven Y Chang, Calvin C Sheng, Benjamin Van Tassell, Aldo Bonaventura, Alessandra Vecchié, Brenna Carey, Qiuqing Wang, Katherine E Wolski, Prabalini Rajendram, Abhijit Duggal, Tisha S Wang, John F Paolini, Bruce C Trapnell, Deborah Gladish, Karen Myers